“Is Curing Patients a Sustainable Business Model?” Goldman Sachs Analysts Ask

As reported by CNBC, Goldman Sachs analysts are questioning the long-term profitability of “one shot cures” using gene therapy, gene editing and genetically-engineered cell therapy. In a report titled “The Genome Revolution,” analysts framed a fundamental question about medical care in a way that makes it clear shareholders are more valued than patients: “Is curing patients a sustainable business model?” Overall, the firm is optimistic about the growth...

Read the Full Article for Free!

You can unsubscribe at any time and I guarantee the privacy of your email. View our privacy policy

Subscribe for FREE to the #1 Natural Health Newsletter or Login for Instant Access

Unlock censored health information that Google doesn't want you to read

Keep your privacy secure — we are one of the few websites that have banned all Google and Facebook scripts to help stop their surveillance capitalism

Get access to all of Dr. Mercola's health articles, E-books and special reports